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Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America
Infection with HIV is an important risk factor for tuberculosis (TB). Approximately a half-million cases of TB attributable to HIV infection occur worldwide each year, and TB accounts for ∼10% of all AIDS-related deaths among adults [1] . HIV infection may also have an indirect effect on the incidence of TB by increasing transmission rates of Mycobacterium tuberculosis, with negative consequences for both HIV-negative and HIVpositive persons [2, 3] . Although the risk of developing TB is reduced by 70%-90% among HIV-infected persons receiving HAART, compared with untreated individuals [4] [5] [6] [7] , TB continues to occur [8] . Furthermore, TB has become relatively more common when considered as a proportion of all AIDS-associated opportunistic infections [9] . Whether the occurrence of TB among HAART-treated patients is caused by a lack of response to HAART, whether it is linked to an inability of HAART to completely reconstitute the immune system, or whether these cases would have occurred anyway in the absence of HIV infection is unclear.
Our understanding of the possible impact of HAART on HIV-associated TB remains limited. Although the incidence of TB after starting HAART has been estimated, little information is available on the relationship between the risk of TB after starting HAART and either preexisting immunodeficiency or virological and immunological responses to HAART. We analyzed data from the Antiretroviral Therapy (ART) Cohort Collaboration [10] to obtain estimates of the incidence of TB among patients receiving HAART and to identify potential determinants of this incidence.
METHODS
The ART Cohort Collaboration is an international collaboration of cohort studies from Europe and North America set up to describe the prognosis of antiretroviral-naive patients starting HAART for the first time. The study has been described in detail elsewhere [10] . Prospective cohort studies were eligible for inclusion if they had enrolled at least 100 antiretroviralnaive patients with HIV-1 infection aged у16 years who had started HAART with at least 3 drugs, including nucleoside reverse-transcriptase inhibitors, protease inhibitors, and/or nonnucleoside reverse-transcriptase inhibitors. The data set utilized in the current analysis was collected at the start of 2003 and includes data for patients starting HAART between 1996 and early 2003 from 12 cohorts: the AIDS Therapy Evaluation Project-Netherlands, the Aquitaine Cohort, the HAART Observational Medical Evaluation and Research cohort study from the British Columbia Centre for Excellence in HIV/AIDS, Collaborations in HIV Outcomes Research, EuroSIDA, the Frankfurt HIV Cohort, the French Hospital Database on HIV, the Italian Cohort of Antiretroviral-Naive Patients, the Koln/Bonn Cohort, the Royal Free Hospital Cohort, the South Alberta Clinic Cohort, and the Swiss HIV Cohort Study.
Because the primary aim of this analysis was to describe the incidence of new cases of TB in this cohort, individuals with a prior diagnosis of AIDS (who may have experienced TB before starting HAART) were excluded (information on specific AIDSrelated events previously experienced was not included in the data set). We considered the incidence of TB during the first 3 years after starting HAART and investigated factors associated with this incidence. Person-years of follow-up (PYFU) were calculated from the date of starting HAART until the date of death, the date of last follow-up visit at the clinic, or 3 years after starting HAART, whichever occurred first. The following baseline factors were considered: sex, risk group (men who have sex with men, injection drug user, heterosexual, or other/not known), year of starting HAART (1997 HAART ( or earlier, 1998 HAART ( , 1999 HAART ( , 2000 HAART ( , and 2001 or after), CD4
+ cell count at baseline (stratified as !50, 50-199, 200-349, 350-499 , and у500 cells/mL, and also treated as a continuous variable after a log 2 transformation, so that relative rates reflect the impact of a doubling in the CD4 + count on the TB rate), HIV RNA level at baseline (either !5 or у5 log 10 copies/mL), type of HAART regimen (fitted as binary variables indicating patients who received regimens including protease inhibitors, nonnucleoside reverse-transcriptase inhibitors, or nucleoside reverse-transcriptase inhibitors only; those patients receiving regimens including both protease inhibitors and nonnucleoside reverse-transcriptase inhibitors were included in both groups), age (either р37 or 137 years), and time since starting [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] months after start of HAART, but modelled as a continuous variable by taking the midpoint of each interval [11] ). All analyses were adjusted for cohort to indirectly account for geographical region. Univariable and multivariable Poisson regression models were used to identify factors independently associated with the incidence of TB using the GenMod procedure in the SAS software, version 8 (SAS).
We then considered the incidence of TB in relation to response to HAART. For this analysis, because CD4 + cell counts were only available in the data set at 6 months after starting HAART (the nearest CD4 + cell count within the window of 3-9 months after starting HAART), events and PYFU were only considered after this time point. Poisson regression models were used to identify whether the incidence of TB over this time period was associated with the immunological and virological response to HAART at 6 months after controlling for baseline disease status and for the other risk factors identified in the first analysis. Because analyses that considered the incidence of TB in relation to the baseline CD4 + cell count suggested that the risk of TB increased in an exponential way with a decreasing CD4 + cell count, the final multivariable model included the CD4 + cell counts at baseline and at 6 months as continuous measurements after a log 2 transformation.
RESULTS
In total, 17,142 (77.2%) of the 22,217 patients had no prior AIDS event at the time of starting HAART. The majority of patients were male (74%), were infected with HIV through sexual transmission (75%), and had a CD4 + cell count !350 cells/mL at the time of starting HAART (64%). The majority (63.1%) started a HAART regimen including у1 protease inhibitors (table 1) . The median duration of follow-up for patients in the cohort after starting HAART was 2.8 years (range, 0-7.9 years).
Baseline factors associated with the incidence of TB during the first 3 years of follow-up. During the first 3 years (36,906 PYFU), 173 patients developed a first episode of TB (incidence, 4.69 cases per 1000 PYFU; 95% CI, 3.99-5.39 cases per 1000 PYFU). Two patients died within 2 months after receiving their TB diagnosis; these cases occurred at 2 weeks and 2 years after starting HAART. The TB rate was highest in the first 3 months after starting HAART but decreased with increased exposure to HAART (table 2) . TB rates were higher among women than among men; higher among those infected via heterosexual sex, injection drug users, and those with other or unknown risk factors, compared with men who have sex with men; higher in recent calendar years than earlier; and higher in patients with low CD4 + cell counts and high HIV RNA levels at the time of HAART initiation. Of the 173 cases of TB, 86 (49.7%) were pulmonary and 87 (50.3%) were extrapulmonary; the ratio of pulmonary to extrapulmonary cases did not vary greatly by calendar time, CD4 + cell count, or duration of HAART exposure.
Results from the multivariable Poisson regression analyses (table 3) suggested that rates were lower in men who have sex with men compared with other risk groups and in those starting HAART in 1998 or earlier compared with those starting HAART in later years. In addition, a higher CD4 + cell count at the time of starting HAART was independently associated with a reduced incidence of TB. There was no independent relationship between the baseline HIV RNA level and the incidence of TB after adjustment. TB rates were also higher from 6 months onward in those whose baseline and 6-month RNA levels were higher. In multivariable analyses (table 3) , the CD4 + cell count at 6 months and the baseline CD4 + cell count both remained associated with the incidence of TB from 6 months onward. Individuals with an HIV RNA level 1400 copies/mL at 6 months were at twice the risk of a subsequent TB event, compared with those with lower HIV RNA levels, but an HIV RNA level у100,000 copies/mL at the start of HAART was not significantly associated with the incidence of TB after controlling for the 6-month level and for CD4 + cell counts at the 2 time points (adjusted relative rate, 0.87; 95% CI, 0.53-1.45; ). The relative rates associated P p .60 with the CD4 + cell count at baseline and at 6-months were similar when the analysis was restricted to those with an HIV RNA level !400 copies/mL at 6 months (relative rates, 0.90 and 0.92, respectively), although the estimate for the 6-month value was no longer statistically significant, because of the reduced number of individuals in this analysis. NOTE. MSM, men who have sex with men; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.
DISCUSSION
Analyses of the incidence of TB among individuals receiving HAART have been hampered, even in large cohorts, by the small number of individuals developing the disease. We addressed this issue by analyzing data from patients starting HAART who were enrolled in several cohorts in Europe and North America. The majority of patients were enrolled in countries where annual TB incidence rates in the general population are !20 cases per 100,000 population [12] . Among these patients, we found an overall incidence of TB of 4.7 cases per 1000 PYFU. The CD4 + cell count at the time of starting HAART and the immunological response to treatment measured after 6 months of therapy were both independently associated with the risk of TB over the subsequent 2.5-year period. Although a virological response to HAART was associated with a reduced risk of TB, the baseline HIV RNA level was not. Thus, those at higher risk of TB are those with poorer immunological or virological responses to HAART and those starting HAART with more-advanced immuno-suppression.
Previous European and North American studies conducted in the pre-HAART era reported an increased risk of TB for those with HIV infection, ranging from 1% to 9% per year [13] . In the present analysis, we observed an incidence of 13.1 cases per 1000 PYFU during the first 3 months after starting HAART, a figure approaching that seen for untreated HIVinfected individuals. This observation is consistent with reports that the risk of developing an opportunistic infection may be only slightly reduced in the first months after initiation of HAART [14] . It is possible that this high rate may reflect delayed diagnosis in those whose symptoms were being investigated at the time of initiation of HAART. It is also possible that the high rate may reflect the impact of immune reconstitution [15] , although increases in CD4 + cell count during the first 6 months were similar for patients who developed TB in the first 6 months and patients who developed TB later, suggesting that this explanation was unlikely. Although a striking reduction in incidence of TB was achieved in the first 6 months after starting HAART, the risk of TB continued to decrease over the period of observation among those patients remaining under follow-up. This decrease in risk may reflect a progressive restoration of the ability of the immune system to control M. tuberculosis infection, and it is in agreement with in vitro studies suggesting that restoration of cellular immunity against TB may be delayed after initiation of HAART [16] .
The incidence of TB was associated with the CD4 + cell count before starting HAART, which is consistent with results from studies involving untreated patients [17] . The baseline CD4 + cell count remained associated with the incidence of TB from 6 months after initiation of HAART, even after controlling for the 6-month CD4 + cell count, which was also predictive of the subsequent incidence of TB. These findings are in contrast to earlier analyses, in which the 6-month CD4 + cell count was a stronger predictor of clinical outcomes (all AIDS-related events) for patients receiving HAART than was the baseline CD4 + cell count [18] . Our findings may reflect the fact that patients coinfected with HIV and TB may show minimal recovery of in vitro immunity to TB when HAART is started at low CD4 + cell counts [19] . Thus, we may expect a different relationship when considering TB than when considering all other AIDS-related events. Alternatively, our findings may reflect some degree of residual confounding, either because of the method of incorporation of CD4 + cell counts in the model or because of lack of adjustment for other unmeasured confounders.
Unlike other HIV-associated opportunistic infections, TB may occur at relatively high CD4 + cell counts [20] and may also occur soon after HIV seroconversion [21] . Our results suggest that HAART may reduce the risk of TB to levels observed in the first phase of infection and that, as also suggested by in vitro studies [16, 19, 22] , complete restoration of cellular immunity against TB may not be possible. Some of the cases of TB in individuals with high CD4 + cell counts may be among individuals who have recently been infected with M. tuberculosis, who may remain at increased risk of developing active disease. Unfortunately, we cannot distinguish between new infections and reactivations of latent TB in this study, and therefore, we are unable to determine which of these explanations is most likely.
In our analysis, men who had sex with men had a lower risk of TB, compared with other HIV-infected persons, most likely reflecting the different background prevalence of TB infection in different population groups, different ethnicity profiles, adherence patterns, and/or social or lifestyle factors. Furthermore, the incidence of TB appears to have increased over time. This may be due to a change over time in the underlying population of individuals with HIV infection, because the proportion of individuals immigrating from regions with a high TB prevalence into many European countries has increased. Other limitations of our analysis need to be mentioned. First, we included patients who started HAART as their first regimen, but we have no information on actual receipt of therapy or on the different types of antiretroviral drugs used during followup. Because our analysis aimed to provide information on the risk of TB for individuals who had started HAART, this limitation will not have a major impact on our results. Second, our definition of response to HAART was based on the HIV RNA level and CD4
+ cell count at 6 months after starting HAART. Previous studies have suggested that these values effectively characterize response to HAART in terms of its impact on the risk of developing opportunistic infections [14, 18, [23] [24] [25] . Third, and most importantly, the majority of patients in our analysis were enrolled in countries with a low incidence of TB. Thus, our data will not be generalizable to countries with a high incidence of TB. Fourth, because information was not available on the specific AIDS-defining events that individuals had experienced before starting HAART, we only included individuals who were free of AIDS at initiation of HAART. Thus, our results will only reflect the incidence of TB among AIDSfree individuals starting HAART, and we cannot generalize our results to recurrent TB events, for which a prior history of TB may be a strong risk factor [26] . Furthermore, we cannot rule out the possibility that we have included some recurrences in this analysis, because pulmonary TB started to be considered an AIDS-related event only in 1993 [27, 28] . Fifth, we have not performed any analyses on geographical variability of TB in the study. The cohorts included in the collaboration have very different study designs and use their own methods to achieve standardization of AIDS recording and TB diagnoses, and the use of TB treatment and prophylaxis varies from country to country. However, all analyses have been adjusted to take account of any cohort effects that might exist. Finally, even with this large data set, the number of events is too small to investigate whether the risk factors for TB differ according to the site of TB. Even with widespread use of HAART, HIV-infected individuals remain at a relatively high risk of developing TB. Interventions to improve adherence to HAART and other TB control interventions may reduce the risk still further. Clinical trials have shown that treatment of latent TB infection reduces the risk of developing TB in HIV-infected persons [29] . Because a significant proportion of cases of HIV-associated TB result from the reactivation of latent infection, this intervention may significantly contribute to control of this disease. The effectiveness of treating latent TB infection may be increased in those receiving HAART. It has been shown that the possibility of identifying HIV-infected persons with an exposure to TB by using the tuberculin skin test may be increased among those with an immunological response to HAART [30] , and there is evidence that the protective effect of treatment of latent TB may be greater among those with higher CD4 + cell counts [31] . Thus, the preservation or partial reconstitution of immune function determined by HAART could enhance the protective effect of treatment of latent TB.
In conclusion, our analysis shows that the level of immunodeficiency at which HAART is initiated and the virological and immunological responses to HAART are important determinants of the risk of TB among HIV-infected patients. The use of HAART appears to progressively decrease, but not to abrogate, TB risk. If it is the case, as is also suggested by previous studies [22] , that HAART-treated individuals remain at risk of TB over a prolonged life span, then HAART may have only a limited role as a TB-control measure in countries with a high burden of TB and HIV infection.
